AHK-Cu
- Category
- Skin & Cosmetic
- Administration routes
- Topical
- Regulatory status
- Cosmetic ingredient
AHK-Cu is a copper-binding peptide marketed for hair regrowth and skin support, said to activate the dermal papilla and support collagen. The evidence is almost entirely cell-culture and mechanism work; there are no controlled human trials, so the human case is weak. Safety data is thin, and it is contraindicated in Wilson disease, Menkes disease, and copper allergy. It is not an approved drug; it is sold in cosmetics subject to FDA cosmetic requirements and as unregulated products sold online.
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.
Overview
AHK-Cu (Copper Tripeptide-3) is a synthetic copper peptide made of three amino acids (alanine, histidine, and lysine) bound to a copper ion. Unlike its more famous cousin GHK-Cu, AHK-Cu was specifically engineered for hair and scalp applications. Laboratory experiments found increased isolated follicle elongation and dermal papilla cell proliferation, with changes in apoptosis-related proteins. The decrease in apoptotic cells was not statistically significant, and the study did not establish scalp blood-vessel formation or clinical hair regrowth.
How it works in the body
Binds copper and delivers it to hair follicle cells, where it stimulates the dermal papilla — the signaling center that controls hair growth. It activates genes involved in hair growth while suppressing those that cause follicle shrinkage.
Research overview
AHK-Cu works by stimulating the dermal papilla cells at the base of hair follicles, promoting hair follicle elongation, boosting blood vessel growth factor (VEGF) production, and tipping the balance in follicle cells toward survival rather than programmed cell death. The foundational 2007 study from Seoul National University showed it effectively stimulated human hair follicle growth in lab settings at extremely low concentrations (picomolar to nanomolar range). The broader copper peptide family, including GHK-Cu which has been studied since the 1970s, is known to stimulate collagen and elastin production and support tissue remodeling. However, AHK-Cu research is considerably more limited than GHK-Cu, with only a handful of published studies focused specifically on this variant. Most evidence is from lab and cell culture studies rather than clinical trials in humans.
Who researches AHK-Cu?
Commonly researched by
People exploring tissue repair and injury recovery
Studied for effects on wound healing, tendon/ligament repair, or recovery from injury.
People researching skin health and rejuvenation
Studied for collagen synthesis, skin repair, or anti-aging skin effects.
People researching hair restoration options
Explored for effects on hair follicle stimulation or hair regrowth.
People researching inflammation management
Studied for anti-inflammatory effects across various conditions.
Important considerations for
Those who are pregnant or breastfeeding
AbsoluteNo human reproductive safety data exists for this peptide. Effects on fetal development are unknown.
Anyone under 18
AbsoluteNo pediatric safety data. Not recommended for use in minors.
Those with Known hypersensitivity
AbsoluteDiscontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).
Safety & interactions
General cautions
Pregnancy or breastfeeding
AbsoluteNo human reproductive safety data exists for this peptide. Effects on fetal development are unknown.
Children under 18
AbsoluteNo pediatric safety data. Not recommended for use in minors.
Known hypersensitivity
AbsoluteDiscontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).
How to read the ratings
- Benefits
- = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
- Risks
- = level of concern: High · Moderate · Low · Theoretical
- Interactions
- = direction with this peptide: Protective / Synergistic · Caution · Neutral
Risk summary(12)
Rated by level of concern
Limited long-term safety data — most studies are short-duration in vitro experiments
HighPMID 17703734; no registered or published AHK-Cu human trials identified
Contraindicated in Wilson disease (copper metabolism disorder) and Menkes disease
ModerateEstablished Wilson disease management; copper-histidine is standard Menkes therapy
Contraindicated in individuals with copper allergies
ModerateFage et al., copper hypersensitivity review, Contact Dermatitis 2014
Insufficient safety data for use during pregnancy and breastfeeding — avoid as precaution
ModerateAbsence of published reproductive toxicology for AHK-Cu
Local skin irritation (redness, itching) at application site — generally mild and transient
LowGeneral topical copper-peptide tolerability; no AHK-Cu trial data
Should not be applied to broken, infected, or actively inflamed skin
LowGeneral topical dermatology principle
Short in vivo half-life (<30 minutes in plasma) limits systemic bioavailability
TheoreticalNo AHK-Cu PK study located; the <30-minute figure is unverified
Rapid enzymatic degradation by proteases may reduce efficacy without proper formulation
LowRationale for palmitoylated AHK derivatives; no direct AHK-Cu stability study located
Potential for allergic/hypersensitivity reactions (rare)
LowCopper contact-allergy literature generally (Fage et al., Contact Dermatitis 2014); no AHK-Cu case reports
Potential copper toxicity if combined with oral copper supplements — monitor total copper intake
TheoreticalNo documented case; mechanistic inference
Temporary increased hair shedding in first 4-6 weeks of use (adjustment period)
TheoreticalExtrapolated from minoxidil; no AHK-Cu source
Metallic taste or nausea reported rarely — discontinue if persistent
TheoreticalNo primary source located
Interaction summary(8)
Rated by direction with this peptide
Copper chelation therapy for Wilson disease (penicillamine, trientine, bis-choline tetrathiomolybdate)
CautionModerateApplying an exogenous copper-delivering peptide runs counter to the therapeutic goal of copper depletion and should be avoided by anyone on de-coppering therapy. The absolute copper delivered topically is small and no clinical case of interference is documented, but the avoidance is standard practice in this population.
Established Wilson disease management principle; no AHK-Cu-specific interaction study
Oral copper supplements and copper-containing multivitamins
CautionTheoreticalTotal copper intake is additive in principle, though the copper delivered by topical AHK-Cu at active concentrations is negligible next to dietary and supplemental sources, so this matters mainly in copper-handling disorders.
Mechanistic; no documented case of additive copper toxicity from topical copper peptides
High-dose zinc supplementation
CautionTheoreticalChronic high-dose zinc induces intestinal metallothionein and antagonizes copper absorption — a real systemic copper interaction, but one unlikely to meaningfully alter a topically applied copper peptide.
Established zinc-copper antagonism; no AHK-Cu-specific data
Topical minoxidil
SynergisticTheoreticalMechanisms are complementary and non-overlapping — minoxidil is a potassium-channel opener and vasodilator, while AHK-Cu acts on dermal papilla proliferation and VEGF in vitro — but no combination study in humans or animals exists, so synergy is a hypothesis rather than a finding.
Mechanistic inference; no combination trial identified
Finasteride / dutasteride (5-alpha-reductase inhibitors)
SynergisticTheoreticalDistinct pathways — systemic DHT suppression versus local dermal papilla signaling — with no known pharmacokinetic or pharmacodynamic conflict, but the combination has never been formally tested and the TGF-beta1 rationale sometimes offered for it is unsourced for AHK-Cu.
Mechanistic inference; no combination trial identified
Topical L-ascorbic acid (vitamin C serums) applied at the same time
CautionLowLow-pH ascorbic acid can reduce and destabilize the copper-peptide complex, and copper catalyzes ascorbate oxidation, so co-application in the same layer risks mutual degradation — separating applications is the usual mitigation. This is a formulation-stability issue, not a toxicity one.
Redox/formulation chemistry applied to copper peptides generally
Topical retinoids and alpha/beta hydroxy acids
CautionLowCumulative barrier disruption and additive irritation, plus low-pH acid vehicles that may destabilize the copper-peptide complex; a concern about layering topicals rather than a pharmacologic interaction.
General topical dermatology; no AHK-Cu-specific study
Topical corticosteroids on the same skin area
NeutralTheoreticalNo known chemical interaction, though corticosteroid suppression of fibroblast collagen synthesis would be expected to blunt any AHK-Cu ECM effect if used concurrently on the same site.
Mechanistic inference; no interaction study
Known risks(12)
Local skin irritation (redness, itching) at application site — generally mild and transient
Temporary increased hair shedding in first 4-6 weeks of use (adjustment period)
Potential copper toxicity if combined with oral copper supplements — monitor total copper intake
Contraindicated in Wilson disease (copper metabolism disorder) and Menkes disease
Contraindicated in individuals with copper allergies
Should not be applied to broken, infected, or actively inflamed skin
Insufficient safety data for use during pregnancy and breastfeeding — avoid as precaution
Short in vivo half-life (<30 minutes in plasma) limits systemic bioavailability
Rapid enzymatic degradation by proteases may reduce efficacy without proper formulation
Limited long-term safety data — most studies are short-duration in vitro experiments
Metallic taste or nausea reported rarely — discontinue if persistent
Potential for allergic/hypersensitivity reactions (rare)
Drug interactions(8)
Minoxidil
AHK-Cu and minoxidil may have complementary mechanisms for hair growth. Minoxidil works primarily as a vasodilator while AHK-Cu targets dermal papilla cell survival and proliferation. Can be used together.
Finasteride / Dutasteride
AHK-Cu reduces TGF-beta1 signaling while 5-alpha-reductase inhibitors block DHT production. Complementary anti-hair-loss mechanisms. Can be used together (topical + oral).
GHK-Cu
Complementary copper peptides. GHK-Cu provides broader skin rejuvenation while AHK-Cu targets follicular biology. No contraindications to combined use.
Hyaluronic Acid
Compatible for combined topical use. Hyaluronic acid provides hydration support while AHK-Cu stimulates regeneration.
Vitamin C (L-Ascorbic Acid)
High-dose vitamin C at low pH can destabilize copper peptide complexes and potentially reduce efficacy. Apply at different times or use buffered vitamin C derivatives.
AHA/BHA Acids (Glycolic, Salicylic)
Low-pH chemical exfoliants may destabilize AHK-Cu. Separate application times by several hours or use on alternating days.
Retinoids (Tretinoin, Retinol)
Potential for increased irritation when combining copper peptides with retinoids. Stagger application (e.g., retinoid at night, AHK-Cu in morning) or use on alternating days.
Oral Copper Supplements
Risk of copper toxicity when combining topical copper peptides with oral copper supplementation. Monitor total copper intake. Hepatotoxicity possible with copper overload.
Research & benefits
Evidence base
- Evidence Level
- Preclinical
- Total Studies
- 5
- Human Studies
- 0
The primary evidence comes from the Pyo et al. (2007) study at Seoul National University, which demonstrated AHK-Cu stimulates hair follicle elongation ex vivo and DPC proliferation in vitro using human tissue. The study employed rigorous methods including flow cytometry and Western blotting. Additional supportive evidence comes from the broader copper peptide literature, particularly the extensive GHK-Cu research base. The tripeptide class has been validated in multiple wound healing and skin regeneration studies.
Researched for(12)
Rated by confidence in the evidence
Stimulates hair follicle elongation and extends the anagen (active growth) phase
SpeculativeSingle ex vivo human follicle study measured elongation; anagen-phase extension is inferred, not directly shown.
PMID 17703734 (elongation only; anagen extension is inference)
Promotes dermal papilla cell proliferation at picomolar to nanomolar concentrations
SpeculativeDose-dependent effect shown in cultured human dermal papilla cells in one 2007 study, never replicated.
PMID 17703734
Anti-apoptotic effects: increases Bcl-2/Bax ratio, reduces cleaved caspase-3 and PARP
LowShown in vitro/ex vivo: AHK-Cu raised Bcl-2/Bax and lowered cleaved caspase-3, PARP in human dermal papilla cells.
Pyo HK et al., Arch Pharm Res 2007;30(7):834-839, PMID 17703734 (human dermal papilla cells and ex vivo hair follicles, 10^-9 M AHK-Cu; Bcl-2 up/Bax down p<0.05; cleaved caspase-3 down 42.7% p<0.05; PARP cleavage fragments down 77.5% p<0.05)
Upregulates vascular endothelial growth factor (VEGF) for improved blood supply to follicles and skin
SpeculativeVEGF increase shown in cultured dermal papilla cells; improved blood supply is an unproven inference.
PMID 17703734 (VEGF in dermal papilla cells); vascular benefit is inference
Reduces TGF-beta1 signaling, which may counteract DHT-mediated follicle miniaturization
SpeculativeNo direct AHK-Cu evidence; DHT-miniaturization link is a hypothesis from the GHK-Cu peptide class.
Mechanistic hypothesis and GHK-Cu class extrapolation; no verified AHK-Cu source for TGF-beta1
Stimulates collagen type I expression in dermal fibroblasts
SpeculativeNo AHK-Cu fibroblast data exists; based on GHK-Cu class evidence and copper's lysyl oxidase role.
Class extrapolation from GHK-Cu plus copper/lysyl-oxidase mechanism; no AHK-Cu primary source located
Promotes elastin and glycosaminoglycan (including hyaluronic acid) synthesis
SpeculativeNo AHK-Cu-specific studies exist; extrapolated from GHK-Cu data and copper's elastin cofactor role.
Class extrapolation from GHK-Cu; no AHK-Cu primary source located
Supports extracellular matrix remodeling and tissue repair
SpeculativePlausible from dermal papilla cell data, but no AHK-Cu wound-healing or tissue-repair study exists.
Mechanistic inference and GHK-Cu extrapolation; no AHK-Cu primary source located
Enhances angiogenesis by stimulating endothelial cell migration to wound sites
SpeculativeInferred from reported VEGF upregulation; endothelial migration itself has never been tested for AHK-Cu.
Mechanism-only for AHK-Cu
Antioxidant properties through copper-mediated enzymatic reactions
SpeculativeMechanism-only, based on copper's role as a cofactor for antioxidant enzymes, with no AHK-Cu data.
Mechanism-only; no AHK-Cu primary source located
Anti-inflammatory effects that benefit stressed or sensitive skin
SpeculativeNo AHK-Cu inflammation studies exist; claim is borrowed from the GHK-Cu peptide literature.
Mechanism-only; no AHK-Cu primary source located
Supports skin barrier function and hydration retention
SpeculativeNo published AHK-Cu data on skin barrier or hydration measures; based on cosmetic marketing claims.
No primary source located
Benefits(12)
Stimulates hair follicle elongation and extends the anagen (active growth) phase
Promotes dermal papilla cell proliferation at picomolar to nanomolar concentrations
Anti-apoptotic effects: increases Bcl-2/Bax ratio, reduces cleaved caspase-3 and PARP
Upregulates vascular endothelial growth factor (VEGF) for improved blood supply to follicles and skin
Reduces TGF-beta1 signaling, which may counteract DHT-mediated follicle miniaturization
Stimulates collagen type I expression in dermal fibroblasts
Promotes elastin and glycosaminoglycan (including hyaluronic acid) synthesis
Supports extracellular matrix remodeling and tissue repair
Enhances angiogenesis by stimulating endothelial cell migration to wound sites
Antioxidant properties through copper-mediated enzymatic reactions
Anti-inflammatory effects that benefit stressed or sensitive skin
Supports skin barrier function and hydration retention
Key studies(4)
Pyo HK, Yoo HG, Won CH, Lee SH, Kang YJ, Eun HC, Cho KH, Kim KH
Archives of Pharmacal Research
2007
AHK-Cu at 10^-12 to 10^-9 M stimulated hair follicle elongation ex vivo and dermal papilla cell proliferation in vitro. Reduced apoptosis markers (caspase-3, PARP) and increased Bcl-2/Bax ratio. Conducted at Seoul National University, Department of Dermatology.
Pickart L, Margolina A
International Journal of Molecular Sciences
2018
Comprehensive review of GHK-Cu showing it affects ~31.2% of human genes. Demonstrated 70% collagen production improvement, stimulated blood vessel and nerve outgrowth, and showed protective actions including anti-inflammatory, antioxidant, and anti-cancer properties. Provides mechanistic context for copper peptide class including AHK-Cu.
Pickart L, Vasquez-Soltero JM, Margolina A
BioMed Research International
2015
Detailed review of GHK as a modulator of cellular pathways in skin regeneration. Demonstrated collagen, elastin, and glycosaminoglycan synthesis stimulation. Provides foundational copper peptide science applicable to AHK-Cu mechanisms.
Adnan SB, Maarof M, Fauzi MHB, Fadilah NIM
International Journal of Medical Sciences
2025
Comprehensive review confirming tripeptides regulate cell migration, proliferation, differentiation, inflammation, angiogenesis, and ECM remodeling. Noted critical barriers: short in vivo half-life (<30 min), poor skin penetration, rapid enzymatic degradation. Tripeptides offer low-cost synthesis, low immunogenicity, and high biocompatibility.
Regulation & availability
Why researchers look at it
A 2007 Seoul National University study showed this GHK-Cu derivative promoted human hair follicle growth at remarkably low concentrations (picomolar range) while boosting VEGF production and tipping follicle cells toward survival. Unlike its well-known cousin GHK-Cu, AHK-Cu was specifically engineered for hair loss. No large-scale human trials exist yet, but if future studies confirm its targeted efficacy at such low doses, it could carve out a distinct niche in peptide-based hair restoration.
- Estimated cost
- $20-60/mo in OTC hair/skin serums
- FDA status
- Not FDA-approved as a drug or biologic. AHK-Cu is classified as a cosmetic ingredient when used in topical skincare and haircare products. It is not regulated as a pharmaceutical. No FDA New Drug Application (NDA) or Investigational New Drug (IND) applications are publicly listed for AHK-Cu. The peptide falls under cosmetic regulations when marketed for appearance-related claims (e.g., hair appearance, skin texture) rather than therapeutic claims. No FDA monograph exists for this compound.
- WADA status
- AHK-Cu is not named in the 2026 WADA List. This does not establish clearance: S0 and class-based provisions may cover unnamed substances. Obtain a compound-specific determination from the relevant anti-doping organization.
- Prescribability
- AHK-Cu is not an FDA-approved drug and is not prescribed by physicians. It is sold as a topical cosmetic raw material or in finished skincare/haircare formulations.
- Availability
- Sold as raw powder (99% purity), liposomal solutions (e.g., 10% AHK-Cu liposome), and in finished haircare/skincare formulations. Not available as a pharmaceutical product. Topical formulations are the primary delivery method; injectable forms are not commercially available for this peptide. CAS number: 682809-81-0.
International status
EU
Not approved
US
Not FDA-approved as a drug. Products making only cosmetic appearance claims are subject to cosmetic requirements; hair-regrowth claims trigger drug requirements.
Worldwide
No regulatory approval in any jurisdiction
Regulatory timeline(6)
- 2007Foundational study by Pyo et al. at Seoul National University published in Archives of Pharmacal Research, reporting AHK-Cu effects on hair follicle elongation and DPC proliferation in vitro (PMID: 17703734)
- 2015Pickart et al. published comprehensive review of GHK peptide in skin regeneration (PMC4508379), providing broader mechanistic context for copper peptide class
- 2018Pickart & Margolina published updated review of GHK-Cu regenerative and protective actions with gene data (PMC6073405), further validating copper peptide mechanisms
- 2020AHK-Cu gains commercial traction in cosmetic and haircare markets. CAS 682809-81-0 registered.
- 2025Adnan et al. published comprehensive tripeptide review in International Journal of Medical Sciences (DOI: 10.7150/ijms.118118), validating tripeptide mechanisms in wound healing and skin regeneration
- 2026AHK-Cu remains classified as a cosmetic ingredient. No FDA drug approval process initiated. Growing presence in consumer haircare and anti-aging formulations. Research base expanding but still limited compared to GHK-Cu.
Sources & FAQs
Research sources(5)
- The effect of tripeptide-copper complex on human hair growth in vitro
- Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data
- GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration
- Exploring the Role of Tripeptides in Wound Healing and Skin Regeneration: A Comprehensive Review
- AHK-Cu Overview, Dosing & Safety
Frequently asked questions(5)
What is the difference between AHK-Cu and GHK-Cu?
GHK-Cu (Glycine-Histidine-Lysine copper) is a naturally occurring peptide found in human plasma that declines with age. It has been studied since the 1970s and affects approximately 4,000 human genes, making it broadly useful for skin rejuvenation, wound healing, and anti-aging. AHK-Cu (Alanine-Histidine-Lysine copper) is a synthetic analog where glycine is replaced with alanine. It was specifically engineered for hair follicle applications and has a more targeted research base focused on dermal papilla cell stimulation and hair growth. GHK-Cu is considered the gold standard for overall skin health, while AHK-Cu is preferred for hair-specific applications.
How long does AHK-Cu take to show results for hair growth?
The cited laboratory study cannot establish when visible hair growth or initial shedding might occur in people.
Is AHK-Cu safe?
AHK-Cu has a favorable safety profile in topical applications based on available data. Common side effects are mild and include local redness, itching, and temporary increased shedding. It is contraindicated in individuals with copper allergies, Wilson disease, or Menkes disease. It should not be applied to broken or infected skin. Caution is advised during pregnancy and breastfeeding due to lack of safety data. No serious adverse events have been reported in the literature.
How do AHK-Cu and GHK-Cu differ?
GHK-Cu provides broader skin rejuvenation and anti-aging benefits, while AHK-Cu targets hair follicle health specifically. Some formulations contain both peptides, and no contraindications to using them together are known.
At what concentration is AHK-Cu effective?
Research by Pyo et al. (2007) showed efficacy at extremely low concentrations of 10^-12 to 10^-9 M in vitro. For topical formulations, concentrations of 0.5-1% are most commonly used, with a range of 0.3-2% in finished products. The optimal pH range for formulations is 5.0-7.0. Storage should be at 2-8 degrees Celsius in dark glass containers, and prepared solutions should be used within 30 days.